Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing…
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota…